Drug intelligence / Profile preview

SLV342

Development stage: Discontinued
Lead developer: Abbott
Modality: Small Molecules
Administration: Oral

Overview

SLV342 is a selective neuropeptide Y receptor Y2 (NPY2R) agonist that was developed by Solvay Pharmaceuticals and later Abbott Laboratories. It was designed as an anti-obesity agent to mimic the satiety-inducing effects of the endogenous peptide YY (PYY). By activating NPY2 receptors in the arcuate nucleus of the hypothalamus, SLV342 aimed to reduce appetite and food intake. The compound entered Phase 1 clinical trials (NCT00663910) to evaluate its safety, tolerability, and pharmacokinetics in healthy male subjects. However, development was discontinued following Abbott's acquisition of Solvay in 2010.

Targets

NPY2R (Neuropeptide Y receptor subtype 2)

Beyond the preview

Go deeper on SLV342.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLV342.

Explore the full profile